Premium
Stanniocalcin1 gene expression in patients with acute leukemia: impact on response to therapy and disease outcome
Author(s) -
Abaza H. M. H.,
Elmougy M. I.,
El Maraghy H. M. A.,
Mahmoud H. M.
Publication year - 2016
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.12445
Subject(s) - medicine , myeloid leukemia , acute leukemia , gene expression , real time polymerase chain reaction , leukemia , oncology , clinical significance , disease , immunology , gastroenterology , gene , biology , biochemistry
Summary Introduction Stanniocalcin1 ( STC 1 ) is a hormone that regulates cell growth and survival; this study aimed to evaluate the STC 1 gene expression in patients with acute leukemia and assess its prognostic significance. Methods Seventy‐six patients with acute leukemia were enrolled for determination of mRNA STC 1 by real‐time quantitative polymerase chain reaction at diagnosis and at day 28. Results Median STC 1 gene expression was 16.2 and 4.43 in patients with acute myeloid leukemia and 9.67 and 2.37 in patients with acute lymphoblastic leukemia on days 0 and 28, respectively. A cutoff level for STC 1 gene expression was established subdividing patients into high‐ and low‐ STC 1 gene expression groups. Median STC 1 gene expression at days 0 and 28 was significantly higher among patients who were nonresponders to therapy than among those who were therapy responders in both groups. Patients achieving complete remission had significantly lower baseline STC 1 gene expression than those in relapse. High STC 1 gene expression was associated with shorter overall and disease‐free survival times. Conclusion STC 1 gene expression at diagnosis might be a useful prognostic marker for clinical outcome and monitoring therapeutic response in patients with acute leukemia.